Sandoz, Teva, and TWi Pharmaceuticals announced the launch of Guanfacine HCl Extended-Release Tablets, the generic version of Shire’s Intuniv.

Intuniv is a central alpha-2A agonist indicated for the treatment of attention deficit hyperactivity disorder (ADHD), as monotherapy or as an adjunct to stimulant medications. Guanfacine is a known antihypertensive agent; its exact mechanism of action of guanfacine in ADHD is not known.

RELATED: New ADHD Treatment Coming Soon

Guanfacine Extended-Release Tablets are available in 1mg, 2mg, 3mg, and 4mg strengths.

For more information visit,, and